Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home

Retrieved on: 2024-05-17 19:26:54

Tags for this article:

Click the tags to see associated articles and topics

Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home. View article details on hiswai:

Excerpt

Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive ...

Article found on: www.onclive.com